MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
BioCardia Retained Earnings 2011-2025 | BCDA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings BioCardia
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -152 M | -141 M | -129 M | - | -101 M | -86.4 M | -72.4 M | -60.1 M | -12.1 M | -12.5 M | -12.7 M | -12.7 M | -13 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.1 M | -152 M | -67 M |
Quarterly Retained Earnings BioCardia
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -166 M | -165 M | -163 M | -160 M | -158 M | -156 M | -154 M | -152 M | -150 M | -148 M | -144 M | -141 M | -138 M | -135 M | 138 M | -129 M | -125 M | -123 M | -119 M | -116 M | -116 M | -116 M | -116 M | -101 M | -101 M | -101 M | -101 M | -86.4 M | -86.4 M | -86.4 M | -86.4 M | -72.4 M | -72.4 M | -72.4 M | -72.4 M | -60.1 M | -60.1 M | -60.1 M | -60.1 M | -49.8 M | -12.1 M | -12.1 M | -12.1 M | -12.1 M | -12.5 M | -12.5 M | -12.4 M | -12.5 M | -12.5 M | -12.6 M | -12.7 M | -12.7 M | -12.7 M | -12.7 M | -12.7 M | -13 M | -13 M | -13 M | -13 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 138 M | -166 M | -76.6 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.79 | 2.35 % | $ 795 M |  Canada |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B |  USA |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 3.04 | 4.83 % | $ 235 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-248 M | $ 0.93 | -8.81 % | $ 257 K | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 212.81 | 1.71 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioVie
BIVI
|
-352 M | $ 1.27 | -3.05 % | $ 1.88 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.1 | 0.16 % | $ 7.46 B |  Australia |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 12.37 | 2.06 % | $ 814 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-1.4 B | - | - | $ 7.29 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 26.83 | 0.94 % | $ 1.73 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Celsion Corporation
CLSN
|
-407 M | - | -6.63 % | $ 13.9 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 95.03 | 0.95 % | $ 27.2 B | Germany |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
544 M | $ 83.59 | 1.95 % | $ 8.63 B | USA |
 |
Anika Therapeutics
ANIK
|
128 M | $ 9.48 | 0.96 % | $ 139 M | USA |
 |
CorMedix
CRMD
|
-322 M | $ 12.19 | 1.75 % | $ 621 M | USA |
 |
Cortexyme
CRTX
|
-320 M | - | -1.05 % | $ 67.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 0.18 | -25.03 % | $ 392 M |  Israel |
 |
CTI BioPharma Corp.
CTIC
|
-2.52 B | - | - | $ 1.2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 591.15 | 0.02 % | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 92.45 | 0.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |